Monitor QUELL trial results in Q4 2026 as the next major catalyst for IHEEZO adoption. The interim data is supportive but not definitive; near-term stock movement may be muted until topline results.
Price Chart
Executive Summary
Harrow presented three studies at ASRS 2026 supporting IHEEZO and BYOOVIZ, including interim randomized data suggesting improved patient experience and a large real-world safety analysis. No financial results or regulatory decisions were announced; the key upcoming catalyst is QUELL trial topline data expected in Q4 2026.
Key Facts
- Interim randomized study (150 patients) comparing IHEEZO vs subconjunctival lidocaine showed encouraging trends in post-procedure pain and patient experience.
- Real-world study across ~20,000 injections found no increased endophthalmitis risk with IHEEZO vs legacy preparation.
- QUELL trial (≈236 subjects) topline data expected Q4 2026.
- Samsung Bioepis presented interim real-world post-marketing surveillance data for BYOOVIZ.
Financial Impact
No financial figures disclosed; clinical data updates support product adoption but no immediate revenue impact.
Risk Factors
- QUELL trial may fail to meet endpoints, undermining IHEEZO's value proposition.
- Competition from other ocular anesthetics and biosimilars could limit market share.
- Retrospective safety data does not guarantee prospective outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329596 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $30.58 $30.35 | ▼ −0.75% | ▼ −1.30% | $28.95 (−5.33%) |
Oct 5, 2026 21d ago | Press Release | $30.58 $30.35 | ▼ −0.75% | ▼ −1.30% | $28.95 (−5.33%) |
Aug 10, 2026 11w ago | 8-K | $39.42 $39.36 | ▼ −0.15% | ▼ −0.40% | $28.95 (−26.56%) |
Aug 10, 2026 11w ago | Press Release | $39.42 $39.36 | ▲ +0.15% | ▲ +0.40% | $28.95 (+26.56%) |
Aug 6, 2026 11w ago | 8-K | $39.92 $40.44 | ▲ +1.30% | ▲ +0.69% | $28.95 (−27.48%) |
Jul 27, 2026 13w ago | Press Release | $37.46 | awaiting T+1 | — | $28.95 (−22.72%) |
Jul 20, 2026 14w ago | Press Release | $44.45 $43.71 | ▼ −1.66% | ▼ −2.50% | $28.95 (−34.87%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.64 $38.93 | ▲ +3.43% | ▲ +1.66% | $28.95 (−23.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.65 $37.64 | ▼ −0.03% | ▼ −0.57% | $28.95 (−23.11%) |
Jun 3, 2026 20w ago | 8-K | $33.32 $34.69 | ▲ +4.11% | ▲ +3.71% | $28.95 (−13.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers